

Reference:	FOI.10119.22
Subject:	Migraine treatment
Date of Request:	26 October 2022

Requested:

- How many patients have been treated with the following drugs in the past 4 months:
 - Erenumab (Aimovig) - any disease
 - Fremanezumab (Ajovy) - any disease
 - Galcanezumab (Emgality) - any disease
 - Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - migraine ONLY
- How many patients have you treated in the last 4 months for chronic migraine (15+ headache days per month) and episodic migraine (4-15 headache days per month) with the following drugs:

Drugs	Chronic Migraine (15+ headache days per month)	Episodic Migraine (15+ headache days per month)
Erenumab		
Fremanezumab		
Galcanezumab		
Botulinum Toxin		

Response:

Hywel Dda University Health Board (UHB) is unable to provide you with the information requested for question 2, as it is estimated that the cost of answering your request would exceed the “appropriate limit” as stated in the Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulations 2004. The “appropriate limit” represents the estimated cost of one person spending 18 hours (or 2½ working days) in determining whether the UHB holds the information, and locating, retrieving and extracting the information.

In order to provide you with the data requested, the UHB would need to undertake a manual trawl of all of the identified prescriptions and cross reference with the patient’s medical record, to identify the reason for treatment.

I can confirm that 119 patients have been treated with the named medications during the requested timeframe. It is estimated that conducting a search to identify the requested information would cost:

119 @ 30 minutes per item = 59.5 hours
59.5 hours @ £25 per hour = £1,487.50

The UHB is therefore applying an exemption under Section 12 of the Freedom of Information Act 2000 (FoIA), which provides an exemption from a public authority’s obligation to comply with a request for information where the cost of compliance is estimated to exceed the appropriate limit.

However, under section 16 of the Freedom of Information Act, the UHB has a duty to provide advice and assistance. Therefore, the UHB has provided the information requested in response to question 1 below.

1. The table below provides the number of patients treated with the named medications between 1 June and 30 September 2022.

Medication	Number
Erenumab (Aimovig)	*
Fremanezumab (Ajovy)	20
Galcanezumab (Emgality)	0
Botulinum Toxin i.e., Botox, Dysport, Xeomin	97

* Where the figures in the table have been replaced with an asterisk, the UHB is unable to provide you with the exact number of patients due to the low numbers of cases (5 and under), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the Data Protection Act (DPA) 2018 / General Data Protection Regulations (GDPR) 2016, as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles 6 and 9 of the GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

In reaching this decision, the Data Protection Act 2018 / General Data Protection Regulations 2016 defines personal data as data which relates to a living individual who can be identified solely from that data or from that data and other information which is in the possession of the data controller.